Jackson Thornton Wealth Management LLC Invests $272,000 in Pfizer Inc. $PFE

Jackson Thornton Wealth Management LLC bought a new position in shares of Pfizer Inc. (NYSE:PFE) during the second quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor bought 10,617 shares of the biopharmaceutical company’s stock, valued at approximately $272,000.

A number of other large investors also recently modified their holdings of the stock. GKV Capital Management Co. Inc. bought a new stake in shares of Pfizer during the first quarter worth approximately $27,000. North Capital Inc. bought a new stake in shares of Pfizer during the first quarter worth approximately $28,000. Bayforest Capital Ltd bought a new stake in shares of Pfizer during the first quarter worth approximately $28,000. Harbor Asset Planning Inc. bought a new stake in shares of Pfizer during the second quarter worth approximately $29,000. Finally, Horizon Financial Services LLC bought a new stake in shares of Pfizer during the first quarter worth approximately $35,000. 68.36% of the stock is currently owned by institutional investors and hedge funds.

Pfizer Stock Up 0.7%

Shares of NYSE:PFE opened at $24.68 on Tuesday. Pfizer Inc. has a 52 week low of $20.92 and a 52 week high of $29.22. The company has a debt-to-equity ratio of 0.65, a quick ratio of 0.85 and a current ratio of 1.16. The company has a market capitalization of $140.33 billion, a PE ratio of 13.13, a PEG ratio of 0.81 and a beta of 0.55. The company has a 50 day moving average price of $24.89 and a two-hundred day moving average price of $24.12.

Pfizer (NYSE:PFE) last issued its quarterly earnings data on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.58 by $0.20. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. The company had revenue of $14.65 billion during the quarter, compared to the consensus estimate of $13.43 billion. During the same quarter in the prior year, the firm earned $0.60 earnings per share. The firm’s revenue was up 10.3% compared to the same quarter last year. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. Analysts forecast that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Monday, December 1st. Stockholders of record on Friday, November 7th will be given a dividend of $0.43 per share. The ex-dividend date of this dividend is Friday, November 7th. This represents a $1.72 annualized dividend and a dividend yield of 7.0%. Pfizer’s dividend payout ratio is currently 91.49%.

Wall Street Analyst Weigh In

A number of research firms recently weighed in on PFE. Citigroup boosted their price target on shares of Pfizer from $25.00 to $26.00 and gave the stock a “neutral” rating in a research note on Wednesday, August 6th. Weiss Ratings reissued a “hold (c-)” rating on shares of Pfizer in a research note on Wednesday, October 8th. Wall Street Zen downgraded shares of Pfizer from a “buy” rating to a “hold” rating in a research note on Sunday, September 28th. UBS Group reaffirmed a “neutral” rating and issued a $28.00 target price on shares of Pfizer in a research note on Wednesday, October 1st. Finally, Morgan Stanley lowered their target price on shares of Pfizer from $33.00 to $32.00 and set an “equal weight” rating for the company in a research note on Friday, October 10th. Two equities research analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, eleven have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company has an average rating of “Hold” and an average target price of $28.13.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.